Form 8-K - Current report:
SEC Accession No. 0001701541-25-000014
Filing Date
2025-03-06
Accepted
2025-03-06 16:01:24
Documents
15
Period of Report
2025-03-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bdtx-20250306.htm   iXBRL 8-K 26761
2 EX-99.1 bdtx-exhibit991_q42024.htm EX-99.1 54775
6 GRAPHIC logo.jpg GRAPHIC 14262
  Complete submission text file 0001701541-25-000014.txt   230398

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdtx-20250306.xsd EX-101.SCH 1833
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdtx-20250306_lab.xml EX-101.LAB 22530
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdtx-20250306_pre.xml EX-101.PRE 13077
17 EXTRACTED XBRL INSTANCE DOCUMENT bdtx-20250306_htm.xml XML 2833
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39200 | Film No.: 25715096
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)